Physician profile
Anna N Hetzer
NPI 1851950349
$4,235.90
in general payments reported to CMS, 2019-2025
16 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $51.01 · 2021: $327 · 2022: $722 · 2023: $1,390 · 2024: $1,151 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,374.89 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $766.32 | 2022-2024 | Infuse, Miebo |
| Alcon Vision LLC | $543.03 | 2021-2025 | Total30, Wavelight Refractive Suite, Precision7 |
| Abbvie INC. | $291.84 | 2022-2025 | |
| Coopervision INC. | $170.64 | 2020-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Dompe US, INC. | $145.64 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.29 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $132.63 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $132.45 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $121.83 | 2022 | |
| Rxsight INC | $118.47 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
| Allergan, INC. | $111.30 | 2019 | |
| Sun Pharmaceutical Industries INC. | $63.88 | 2022-2023 | Cequa |
| Oyster Point Pharma, INC. | $47.17 | 2023-2024 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $42.17 | 2023-2024 | Iyuzeh |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $28.35 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Hetzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.